travoprost and Sturge-Weber-Syndrome

travoprost has been researched along with Sturge-Weber-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for travoprost and Sturge-Weber-Syndrome

ArticleYear
Sturge-Weber syndrome and glaucoma.
    Optometry (St. Louis, Mo.), 2011, Volume: 82, Issue:5

    Sturge-Weber syndrome (SWS) belongs to a group of disorders known as the phakomatoses. It is characterized by congenital hamartomatous malformations involving the eye, skin, and central nervous system. Several ocular complications are associated with SWS, including glaucoma.. A 66-year-old black man presented with a history of SWS and previously diagnosed glaucoma.. Clinicians need to be aware of cutaneous, neurologic, and ocular complications of this condition. However, glaucoma is the most common ocular complication of SWS.

    Topics: Aged; Antihypertensive Agents; Cloprostenol; Glaucoma; Humans; Intraocular Pressure; Male; Optic Nerve; Sturge-Weber Syndrome; Travoprost; Treatment Outcome; Visual Acuity

2011
Uveal effusion induced by topical travoprost in a patient with Sturge-Weber-Krabbe syndrome.
    Journal francais d'ophtalmologie, 2008, Volume: 31, Issue:9

    To report a case of uveal effusion with subtotal exudative retinal detachment induced by topical administration of travoprost.. A 20-year-old woman with a medical history of right-sided Sturge-Weber-Krabbe syndrome and bilateral aphakia secondary to congenital cataract extraction was referred to our department for retinal detachment associated with uveal effusion of the right eye. The ocular manifestations of Sturge-Weber-Krabbe syndrome in her right eye were glaucoma and diffuse choroidal hemangioma. Antiglaucomatous medications using topical travoprost 0.004%/timolol 0.5% (fixed combination) had been begun 1 week before. An adverse effect of travoprost was suspected and the drug was discontinued. Three weeks later, a fundus examination showed total disappearance of the uveal effusion.. Interaction of the effects of topical prostaglandin analogs (blood-aqueous barrier disruption, enhancement of uveoscleral outflow) with both the diffuse choroidal hemangioma and the elevated episcleral venous pressure may lead to uveal effusion in Sturge-Weber-Krabbe syndrome. In spite of their efficiency, prostaglandin F2 analogs (latanoprost, travoprost and bimatoprost) should be used with caution in Sturge-Weber-Krabbe syndrome and particularly in cases of proved diffuse choroidal hemangioma.

    Topics: Administration, Topical; Antihypertensive Agents; Body Fluids; Cloprostenol; Female; Humans; Retinal Detachment; Sturge-Weber Syndrome; Travoprost; Uveal Diseases; Young Adult

2008